Digital technologies serving neuroscience
“Our mission, as neuroscience experts in clinical data management and analysis, is to improve the brain health of people with neurological disease through the application of digital technologies.”
As a trusted partner to the global biopharma industry, our technology enabled specialty services are used to, select patients for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance.
Our strong scientific heritage and deep understanding of neurological diseases enable us to collaborate with clinical, academic and pharmaceutical partners to develop and deploy new digital technologies targeted at improving patient outcomes.
We are neuroscience experts in image data management and analysis.
Our greatest assets are our talented people developing and deploying innovative digital technologies.
Quality drives our operational excellence. We support our people to be the best they can be through continuous learning and development.
We conduct our business to the highest ethical standards and strive to be a trusted partner of choice.
Charles joined the Board of IXICO in 2013. He is an experienced Director of, and adviser to, public and private companies primarily in the medtech and life science sectors. He is Non-Executive Chairman of Realm Therapeutics plc, Creo Medical Group plc and 11 Health Technologies Limited and chairs the UK Department of Health Invention for Innovation Funding Panel.
CHIEF FINANCIAL OFFICER
AND COMPANY SECRETARY
Susan joined IXICO as Chief Financial Officer in October 2014. She is an experienced Executive Director with previous Board positions including Group Chief Financial Officer of Novacyt SA and Chief Financial Officer of Lab21 prior to its acquisition by Novacyt. Susan was Chief Financial Officer of BioWisdom until its acquisition by Instem plc and Finance Director of RiboTargets Limited until its acquisition by Vernalis plc.
AND SENIOR INDEPENDENT DIRECTOR
Tim has more than 25 years’ experience in the life sciences sector with various pharmaceutical, biotechnology and pharmaceutical service companies in Europe and the US. He has broad experience in drug development, product licensing, mergers, acquisitions and fundraisings. Previous positions include Chief Executive Officer at Phytopharm PLC and Serentis Limited and Executive Vice President at Vectura PLC. Tim joined the Board of IXICO in 2013 and chairs the Remuneration Committee.
John is a chartered accountant with more than 15 years’ experience as a Chief Financial Officer with venture capital backed and listed companies. He is a partner in Bradshaw Daniel, which provides Chief Financial Officer services and Chief Financial Officer of Syncona Partners LLP, an independent subsidiary of the Wellcome Trust. He was previously Chief Financial Officer of Gyrus Group PLC following 11 years at Arthur Andersen in Cambridge and Turin. John joined the Board of IXICO in 2013 and chairs the Audit Committee.
CHIEF EXECUTIVE OFFICER
Giulio joined IXICO as Chief Executive Officer in February 2017. He has over 30 years of experience in the life sciences sector and a track record of growing business operations in Europe, the US and Asia. Prior to IXICO, Giulio held global leadership roles at ThermoFisher Scientific and the LGC group, where he transformed the scale of LG’s Genomics division, completing 3 acquisitions in under 18 months. Giulio was a member of the executive leadership responsible for the successful sale of the LGC group to global investment firm, KKR.
Derek is a founder of IXICO and has worked in medical imaging science for over 25 years, authoring more than 80 journal papers in this field. He has served on the scientific advisory boards for several pharmaceutical companies and is a member of numerous public/private initiatives seeking to advance the scientific and regulatory agendas supporting the development of therapies to treat neurodegenerative diseases.
Mark joined the Board of IXICO in 2016. He is Head of IP Group’s Healthcare division and has extensive experience in building world-changing healthcare businesses, including portfolio company IPOs, financings and M&A. Mark is a Non-Executive Director of hVIVO plc, Genomics plc, Cronin Group plc and Crysalin Limited.
To speak to one of our experts and find out more